Abstract:BACKGROUND: Cervical cancer (CC) is a common female malignancy, with a global incidence rate second only to breast cancer. OBJECTIVE: To propose a new idea for early treatment and auxiliary diagnosis of CC by exploring the diagnostic and prognostic implications of serum miR-182 in CC. METHODS: We enrolled 70 CC patients, 35 cervical intraepithelial neoplasia (CIN) patients and 35 healthy controls (HCs), who visited The First Affiliated Hospital of Hainan Medical College Hospital between January 2015 and April 2016. miR-182 expression was quantified by real-time quantitative PCR and compared among the three groups. The correlation of serum miR-182 expression with patients' clinical features was evaluated. The receiver operating characteristic curve (ROC) and the Kaplan-Meier method were used to evaluate the early diagnostic value and prognostic value of serum miR-182. Cox regression analysis was performed to determine serum miR-182 expression and its important role in predicting CC patients' prognosis. RESULTS: Serum miR-182 expression was determined to be 0.345 ± 0.094, 0.369 ± 0.076, and 0.586 ± 0.157 in CC patients, CIN patients, and HCs, respectively (P< 0.001). Serum miR-182 expression had an obvious association with lymph node metastasis and pathological differentiation (P< 0.05). The area under the ROC curve (AUC) of serum miR-182 was 0.709 (95% CI: 0.622–0.795), the critical value was 0.456, the sensitivity was 81.4%, and the specificity was 52.9%. CC patients were grouped as either the low- (miR-182 < 0.3) or high-level group (miR-182 ⩾ 0.03) based on serum miR-182 levels, and a Cox regression model of OS was established. Serum miR-182 expression was identified as a factor independently influencing CC patients' OS (P= 0.028); the death risk of the high-level group was 3.246 times that of the low-level group. CONCLUSION: Serum miR-182 expression is not only a biomarker for early diagnosis of CC, but also one of the independent factors influencing the survival and prognosis of CC patients.

Reduced Serum Mir-138 is Associated with Poor Prognosis of Head and Neck Squamous Cell Carcinoma

Downregulation of Mir-138 Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.

Serum miR-626 and miR-5100 are Promising Prognosis Predictors for Oral Squamous Cell Carcinoma.

Diagnostic and Prognostic Implications of a Serum Mirna Panel in Oesophageal Squamous Cell Carcinoma.

Prognostic Significance of Serum Mir-193 B in Colorectal Cancer

In Situ Measurement of Mir-138 Expression in Oral Squamous Cell Carcinoma Tissue Supports the Role of This Microrna As a Tumor Suppressor

Prognostic and Diagnostic Potential of Mir-146A in Oesophageal Squamous Cell Carcinoma.

Serum Mirna Expression in Patients with Esophageal Squamous Cell Carcinoma

Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.

Predictive value of miR-27 b as a potential biomarker for head and neck squamous cell carcinoma

The Microrna-375 As a Potentially Promising Biomarker to Predict the Prognosis of Patients with Head and Neck or Esophageal Squamous Cell Carcinoma: a Meta-Analysis

Mir-145 Expression Level in Tissue Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma.

Prognostic significance of serum miR-193b in colorectal cancer.

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer

Downregulation of Serum Mir-101 is Associated with Worse Prognosis in Non-Small Cell Lung Cancer.

Mir-21 and Mir-375 Micrornas As Candidate Diagnostic Biomarkers in Squamous Cell Carcinoma of the Larynx: Association with Patient Survival.

Serum Mir-133B is a Potential Novel Prognostic Biomarker for Colorectal Cancer

Downregulation of Microrna-139 is Associated with Hepatocellular Carcinoma Risk and Short-Term Survival.

Study on serum miR-182 as a marker for diagnosis and prognosis of cervical cancer

Role of Microrna-138 As a Potential Tumor Suppressor in Head and Neck Squamous Cell Carcinoma.

Combined Identification of Three Mirnas in Serum As Effective Diagnostic Biomarkers for HNSCC